Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study

Abstract Background Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains ins...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Martina Patone, Andrew JHL Snelling, Holly Tibble, Carol Coupland, Aziz Sheikh, Julia Hippisley-Cox
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2025-01-01
Colecção:	Communications Medicine
Acesso em linha:	https://doi.org/10.1038/s43856-024-00720-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!